Inflammatory mediator synthesis pathway

The term "Inflammatory mediator synthesis pathway" does not refer to a single molecule, receptor, or protein but rather describes a collection of biochemical pathways responsible for the production of various inflammatory mediators. These mediators include cytokines, prostaglandins, leukotrienes, histamine, and others that are released by immune cells such as macrophages, mast cells, and neutrophils in response to injury or infection[1][2][4]. The main enzymatic pathways involved are the cyclooxygenase (COX) and lipoxygenase (LOX) pathways that convert arachidonic acid into prostaglandins and leukotrienes respectively[1][4]. These mediators orchestrate the initiation, propagation, and resolution of inflammation through complex cellular interactions. Because "inflammatory mediator synthesis pathway" is not a discrete molecular entity but an umbrella term encompassing multiple enzymes (e.g., COX1/2), receptors (e.g., prostaglandin receptors), and signaling molecules within several interconnected cascades[3][6], it is **not considered a therapeutic target itself**. Instead, individual components within these pathways—such as COX enzymes or specific cytokine receptors—are established drug targets. For example: > Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX enzymes to reduce prostaglandin synthesis; monoclonal antibodies may target pro-inflammatory cytokines like TNF-alpha; other drugs may block leukotriene production or action[6]. Thus, - There is no canonical abbreviation. - It is not itself a therapeutic target. - The entry is incorrect as written because it refers to an entire class of processes rather than a specific molecule or receptor. If you need structured information on specific targets within this pathway—such as "Cyclooxygenase 2," "Tumor necrosis factor alpha," etc.—please specify those molecules individually.